Stock Events

Stock Events

Panbela Therapeutics 

$0.000001
32
-$0.00-99% Thursday 18:20

Statistics

Day High
0.02
Day Low
0.02
52W High
0.1579
52W Low
0.000001
Volume
1,012
Avg. Volume
218
Mkt Cap
4.85
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

20MayExpected
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
-65.9
-44.42
-22.95
-1.47
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-25.26MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PBLA. It's not an investment recommendation.
Tesla
4
TSLA
Alphabet
3
GOOG
Bitcoin
3
BTC.CRYPTO
Ethereum
3
ETH.CRYPTO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that competes in the development of treatments for cancer, a key focus area for Panbela Therapeutics.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech firm focusing on human therapeutics, including cancer treatments which puts it in direct competition with Panbela Therapeutics in the oncology sector.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is known for its strong portfolio in oncology, directly competing with Panbela Therapeutics in the cancer treatment market.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb operates in the biopharmaceutical field, focusing on cancer drugs among other areas, making it a competitor to Panbela Therapeutics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company with a broad range of drugs, including cancer treatments that compete with Panbela Therapeutics' offerings.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, with its extensive research and development in oncology, competes with Panbela Therapeutics in the cancer drug market.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a major player in the pharmaceutical and diagnostics world, with a significant focus on oncology, competing with Panbela Therapeutics.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a strong presence in the oncology sector, developing treatments that compete with Panbela Therapeutics' cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is involved in the discovery, development, and commercialization of medicines for serious medical conditions, including cancer, making it a competitor.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including cancer treatments, competing with Panbela Therapeutics.

About

Panbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients. The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer. Beyond pancreatic diseases, they are also exploring treatments for colorectal cancer, ovarian cancer, and various other oncology indications. Their flagship experimental drug, SBP-101, is currently undergoing Phase Ia/Ib clinical trials, specifically intended for individuals diagnosed with metastatic pancreatic ductal adenocarcinoma. Established in 2011, the company, headquartered in Waconia, Minnesota, rebranded from its prior name, Sun BioPharma, Inc., to Panbela Therapeutics, Inc. in December 2020.
Show more...
CEO
Jennifer K. Simpson
Employees
8
Country
United States
ISIN
US69833W4042
WKN
000A4017G

Listings

STU
DE
X70.STU
MU
DE
X70.MU
OTC Link
US
PBLA

0 Comments

Share your thoughts

FAQ

What is Panbela Therapeutics stock price today?▼
The current price of PBLA is $0.00 USD — it has decreased by -99% in the past 24 hours. Watch Panbela Therapeutics stock price performance more closely on the chart.
What is Panbela Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Panbela Therapeutics stocks are traded under the ticker PBLA.
Is Panbela Therapeutics stock price growing?▼
PBLA stock has fallen by -99% compared to the previous week, the month change is a -99.99% fall, over the last year Panbela Therapeutics has showed a -100% decrease.
What is Panbela Therapeutics market cap?▼
Today Panbela Therapeutics has the market capitalization of 4.85
What is Panbela Therapeutics revenue for the last year?▼
Panbela Therapeutics revenue for the last year amounts to 0 USD.
What is Panbela Therapeutics net income for the last year?▼
PBLA net income for the last year is -25.26M USD.
How many employees does Panbela Therapeutics have?▼
As of September 04, 2026, the company has 8 employees.
In which sector is Panbela Therapeutics located?▼
Panbela Therapeutics operates in the Health & Wellness sector.
When did Panbela Therapeutics complete a stock split?▼
The last stock split for Panbela Therapeutics was on January 18, 2024 with a ratio of 1:20.
Where is Panbela Therapeutics headquartered?▼
Panbela Therapeutics is headquartered in Waconia, United States.